Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged ≥ 18 years
Patients with advanced solid tumors (CRC, melanoma) with documented somatic KRAS or BRAFV600 mutations in tumor tissue. Patients with metastatic pancreatic adenocarcinoma may be enrolled irrespectively of KRAS or BRAFV600 mutational status.
Patients must have relapsed or progressed following standard therapy or patients for whom no standard anticancer therapy exists.
Measurable disease as determined by RECIST v1.1. World Health Organization (WHO) Performance Status (PS) ≤ 2.
Adequate organ function
Negative serum pregnancy test
You may not be if
Prior therapy with MEK- or IGF-1R- inhibitor
History or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or retinal degenerative disease
Patients with known history of severe infusion reactions to monoclonal antibodies
Patients with primary CNS tumor or CNS tumor involvement
History of thromboembolic event requiring full-dose anticoagulation therapy
Clinically significant cardiac disease
History of another malignancy within 2 years
Pregnant or nursing (lactating) women
Clareo Health | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
